Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis

European Journal of Neurology

Volumn 14, Issue 7, 2007, Pages 797-800

  Koch, M ^a   Heersema, D ^a   Mostert, J ^a   Teelken, A ^a   Keyser, J De ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cerebrospinal fluid; Multiple sclerosis; Oligoclonal bands; Progression; Progressive multiple sclerosis

Indexed keywords

OLIGOCLONAL BAND;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DATA BASE; DISABILITY SEVERITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; STATISTICAL ANALYSIS; TISSUE INJURY;

ADOLESCENT; ADULT; AGED; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGOCLONAL BANDS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 34347348243     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.01859.x     Document Type: Article

References (14)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. The New England Journal of Medicine 2000 343 : 938 952.
2. Kuhle J, Lindberg RL, Regeniter A, et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. Journal of Neurology 2007 254 : 160 168.
3. Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2006 103 : 19057 19062.
4. Zeman AZ, Kidd D, McLean BN, et al. A study of oligoclonal band negative multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 1996 60 : 27 30.
5. Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurological Sciences 2000 21 : S831 S838.
6. Avasarala JR, Cross AH, Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Archives of Neurology 2001 58 : 2044 2045.
7. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals Neurology 1983 13 : 227 231.
8. Olsson T, Kostulas V, Link H. Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clinical Chemistry 1984 30 : 1246 1249.
9. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005 64 : 1144 1151.
10. Anon. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998 352 : 1491 1497.
11. Anon. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology 2001 56 : 1496 1504.
12. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006 129 : 584 594.
13. Tintore M, Rovira A, Brieva L, et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Multiple Sclerosis 2001 7 : 359 363.
14. Imrell K, Landtblom AM, Hillert J, Masterman T. Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct. Neurology 2006 67 : 1062 1064.